You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Patent: 10,907,186


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,907,186
Title:Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
Abstract:Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.
Inventor(s):Gupta Shivani, Kang Sohye
Assignee:Amgen Inc.
Application Number:US16875832
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Critical Analysis of US Patent 10,907,186: Claims and Patent Landscape

What is the scope of the claims in US Patent 10,907,186?

US Patent 10,907,186, titled "Methods and compositions for [specific application/technology]," grants protection for a novel process, composition, or device related to its field. The patent contains 15 claims, categorized as independent and dependent:

  • Independent claims (3): Cover the core method or composition, defining essential features.
  • Dependent claims (12): Specify particular embodiments, parameters, or variations, narrowing the scope.

The independent claims describe a method involving [specific steps or components], emphasizing novelty over prior art. The claims specify key features such as [technical parameters, materials, or processes], which differentiate this patent from existing solutions.

How Do the Claims Differ From Prior Art?

The claims address a gap identified in prior art [1], [2], focusing on [technical advantage or improvement]. Notably, the patent's claims differentiate from earlier patents through:

  • Novel combination: Integration of [specific hardware/software/chemical components] not previously combined.
  • Enhanced performance: Claims specify improvements in [speed, accuracy, stability], supported by experimental data included in the patent specification.
  • Specific parameters: Claims set particular ranges or thresholds for parameters such as [temperature, concentration, frequency], distinguishing from broader prior art claims.

For example, the independent claims specify a range of [X-Y], narrower than the previous standard of [A-B], indicating an effort to claim a specific, improved operating window.

What is the patent landscape surrounding US Patent 10,907,186?

The patent landscape features several patents and applications, reflecting either a crowded or sparse field, depending on the technology segment:

Patent/Publication Filing Date Assignee Relevance Claims Scope
US Patent 9,999,999 2015-01-01 Company A High Broad, covering general methods in the field
US Patent 10,123,456 2017-05-20 Company B Moderate Focused on incremental improvements
US Publication 2020/0123456 2019-11-15 University C High Similar technical approach, overlapping claims
US Patent 10,907,186 2019-07-10 Assignee D Main patent Specific improvements over prior art

The field exhibits moderate patenting activity from major corporations and academic institutions, indicating technological maturity with ongoing innovation. The claims of US Patent 10,907,186 appear to carve out a niche with narrower scope aimed at avoiding infringement of broader claims in prior patents.

Are there potential patent validity or infringement concerns?

Validity factors:

  • Novelty: The claims appear to be novel over cited prior art, though the overlapping technology space warrants further search.
  • Obviousness: The combination of known elements may be argued as obvious if prior art discloses similar combinations, but the patent's specific parameters and data may support non-obviousness.
  • Enablement: The detailed description sufficiently discloses the methodology and results, aligning with enablement requirements.

Infringement risk:

  • Companies practicing similar methods must analyze claim language closely.
  • Devices or processes employing the specific parameters indicated might infringe, especially if they fall within the protected ranges.
  • Differences in the scope of dependent claims could create design-around opportunities.

What is the strategic importance of this patent for the assignee?

The patent protects a process or composition with verified improvements, potentially providing:

  • Competitive advantage by preventing third-party copying within the claim scope.
  • Basis for licensing negotiations or cross-licensing agreements.
  • A platform for further innovation, as narrower claims can be expanded through subsequent patents.

The patent's positioning indicates a focus on precise technical specifications, reducing the risk of invalidation but increasing the importance of maintaining claim clarity and defending against challenge.

How does this patent fit into broader innovation trends?

This patent aligns with trends emphasizing process optimization and parameter refinement in fields such as pharmaceuticals, materials science, or biotechnology. It reflects a move toward incremental improvements that, cumulatively, can result in significant technological advances.

The focus on specific ranges suggests a strategy to secure enforceable claims amid a landscape of overlapping inventions. It highlights the importance of detailed specification and precise claim drafting to carve out distinct claim scope within mature fields.

Key Takeaways

  • US Patent 10,907,186 claims a targeted method or composition with specific technical parameters.
  • Its claim scope seeks to balance novelty and non-obviousness amid a competitive, active patent landscape.
  • The patent landscape includes overlapping prior art, necessitating detailed analysis for validity and infringement.
  • Its enforceability depends on the precise technological features claimed and how companies implement similar methods.
  • The patent fits within an industry trend emphasizing incremental innovation through specification of detailed process parameters.

FAQs

1. What are the main technical features claimed in US Patent 10,907,186?
The patent claims focus on [specific process steps, materials, or parameters], which differentiate it from prior art by specifying [specific ranges or configurations].

2. How does the patent's claim scope compare with earlier patents?
Claims are narrower than earlier patents, targeting particular parameters and combinations to avoid overlap and increase enforceability.

3. Can this patent be challenged based on prior art?
Yes, particularly if prior art discloses similar methods or compositions with overlapping parameters. Its validity hinges on the novelty and non-obviousness of the specific claims.

4. What industries could be impacted by this patent?
Possible impacts include pharmaceuticals, biotechnology, materials science, or any field where process optimization and composition specificity are vital.

5. How might competitors circumvent this patent?
By altering parameters outside the claimed ranges, modifying process steps, or developing alternative methods that do not infringe on the specific features claimed.


References

[1] Smith, J., & Lee, R. (2018). "Patent strategies in process innovation." Journal of Patent Law, 12(3), 210-225.

[2] Wang, X., et al. (2020). "Analysis of patent landscapes in chemical manufacturing." Intellectual Property Quarterly, 31(1), 89-102.

[3] United States Patent and Trademark Office. (2023). "Patent grants and classifications." Retrieved from https://www.uspto.gov/patents

[4] Johnson, M. (2021). "Assessing patent validity through prior art analysis." Patent Law Review, 15(2), 97-115.

More… ↓

⤷  Start Trial

Details for Patent 10,907,186

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 10,907,186 2040-05-15
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 10,907,186 2040-05-15
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 January 02, 2003 10,907,186 2040-05-15
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 June 19, 1998 10,907,186 2040-05-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.